about
A novel regulatory mechanism of MAP kinases activation and nuclear translocation mediated by PKA and the PTP-SL tyrosine phosphataseDisruptive chemicals, senescence and immortalityHit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitorsAssessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge aheadConditional transgenic expression of PIM1 kinase in prostate induces inflammation-dependent neoplasiaThe role of PIM1/PIM2 kinases in tumors of the male reproductive systemExploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models.Levels of active tyrosine kinase receptor determine the tumor response to ZalypsisGenetic Modeling of PIM Proteins in Cancer: Proviral Tagging and Cooperation with Oncogenes, Tumor Suppressor Genes, and Carcinogens.Mechanism of action of potato carboxypeptidase inhibitor (PCI) as an EGF blocker.PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases.MAP17 overexpression is a common characteristic of carcinomas.MAP17 enhances the malignant behavior of tumor cells through ROS increase.A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genesTherapeutic inhibition of TRF1 impairs the growth of p53-deficient K-RasG12V-induced lung cancer by induction of telomeric DNA damageSimultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas.PTEN, more than the AKT pathway.The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.Genetic modelling of the PTEN/AKT pathway in cancer research.Inhibiting PI3K as a therapeutic strategy against cancer.Pim kinases in cancer: diagnostic, prognostic and treatment opportunities.The PIM family of serine/threonine kinases in cancer.Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate.Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.The essential role of PIM kinases in sarcoma growth and bone invasion.p38α limits the contribution of MAP17 to cancer progression in breast tumors.PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma.Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition.Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation.Levels of p27(kip1) determine Aplidin sensitivity.Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria.Regulation of MAPK cascades by protein tyrosine phosphatases.Two clusters of residues at the docking groove of mitogen-activated protein kinases differentially mediate their functional interaction with the tyrosine phosphatases PTP-SL and STEP.Inflammation and stem markers association to PIM1/PIM2 kinase-induced tumors in breast and uterus.S-adenosylhomocysteine hydrolase downregulation contributes to tumorigenesis.Down-regulation of spinophilin in lung tumours contributes to tumourigenesis.Modulation of telomere protection by the PI3K/AKT pathway.Correction: Conditional Transgenic Expression of PIM1 Kinase in Prostate Induces Inflammation-Dependent Neoplasia.Inhibition of TRF1 Telomere Protein Impairs Tumor Initiation and Progression in Glioblastoma Mouse Models and Patient-Derived Xenografts.Identification of novel PI3K inhibitors through a scaffold hopping strategy.
P50
Q22010940-55FA7843-6953-4166-AF42-2B195B798658Q27026235-CF865782-1821-487A-9CD0-019B5E115A0DQ27676829-0999B51E-CAE9-4B30-BE86-D60FFA9A6D56Q28397132-B0EBFA1E-3381-4A9F-8875-6A664A8707D0Q28485913-7CB0987B-CAF1-4E93-8B2F-D63297A09FA2Q28818309-70C8BF58-D113-40BB-AA4A-F06D87D4AFAAQ33533301-50258CF0-179B-47CC-9195-AE47D6418625Q33533301-CFEB8BA7-58FF-40A2-B455-723DADE1FCB4Q33622731-6352C7CC-F3D8-4D34-9685-F27AFB07E6E7Q33646972-8AA2037D-7A82-4999-9F1E-1AE2F1D08D9CQ33988847-2CD79005-53C9-4FE3-A881-290A0149B71FQ34489388-36EEF177-D500-4613-A4CF-5ACF76EFF468Q34617889-DE5ED048-B04E-4655-B0C1-3754581C23B6Q34634409-1EC6151E-CAF5-40B0-AAE8-7155ECBA8B45Q35000701-5AA5B3B5-EF96-4631-A8E4-14BFB3571531Q35904248-3CF619F3-357A-445B-8811-D74F7C5769A7Q36498356-2258D333-F6BF-4CB5-B4D6-000D5410A673Q36753139-7018E9BD-F3E0-4E7E-9DD6-D13F6441EF13Q37160617-D8FA52D9-FAA6-4E6C-A9DE-F72694D02C16Q37305035-CD358B9C-21CE-4C92-B308-240EA442E24EQ37602377-991C0019-77C2-4082-ADD1-513D21435517Q38049911-B034FC0B-1D55-4068-BD87-6883A71EC6E2Q38098139-955F5FCE-939F-41A7-8C66-69169AD3BA64Q38303558-10378375-5839-4039-A125-4383B99B2AA2Q39310774-44F13316-D174-4276-B968-14191169FFDEQ39343143-5F2CFF61-C32F-4F79-8E31-5CD07D116BDFQ39408183-F09C7161-A790-4C12-A5E9-C2DB891CB42AQ39470129-9CF75369-A255-4F49-A5DF-F0A8F257F391Q39635683-AB10A387-3400-4B73-B48A-D04518697BBFQ39910389-7E71D8F5-AD55-4548-9024-32718941A86AQ40146329-2E3FF75C-BF33-4CB8-BEFC-4A1D4B4F9A4AQ40373438-DDE4C482-E494-403D-9C12-66B41C184599Q40593789-B62AFC77-8EA9-4210-B1D9-E50A04A243BAQ40768240-33AEB6F1-A42B-4E15-B2FE-DB82897A17DDQ41708939-8EFBFF1B-44AD-4583-B5D8-153586127422Q42809373-7049CE79-669B-43FE-A0EE-3BB86F51260AQ44627811-ADFA663A-C39A-46B9-B9BE-58FF28F965BAQ45329468-B950357E-55E3-408C-8A0B-9D938589DF6DQ45788487-09F1F1A5-CBEE-474D-9646-E7400D49B383Q47404698-714DA265-A8B3-4DDB-98DB-41A256A88CAF
P50
description
Spaans onderzoekster
@nl
hulumtuese
@sq
investigadora española
@ast
researcher
@en
spanische Forscherin
@de
taighdeoir
@ga
հետազոտող
@hy
name
Carmen Blanco-Aparicio
@ast
Carmen Blanco-Aparicio
@ca
Carmen Blanco-Aparicio
@en
Carmen Blanco-Aparicio
@es
Carmen Blanco-Aparicio
@fr
Carmen Blanco-Aparicio
@ga
Carmen Blanco-Aparicio
@nl
Carmen Blanco-Aparicio
@sl
Carmen Blanco-Aparicio
@sq
type
label
Carmen Blanco-Aparicio
@ast
Carmen Blanco-Aparicio
@ca
Carmen Blanco-Aparicio
@en
Carmen Blanco-Aparicio
@es
Carmen Blanco-Aparicio
@fr
Carmen Blanco-Aparicio
@ga
Carmen Blanco-Aparicio
@nl
Carmen Blanco-Aparicio
@sl
Carmen Blanco-Aparicio
@sq
prefLabel
Carmen Blanco-Aparicio
@ast
Carmen Blanco-Aparicio
@ca
Carmen Blanco-Aparicio
@en
Carmen Blanco-Aparicio
@es
Carmen Blanco-Aparicio
@fr
Carmen Blanco-Aparicio
@ga
Carmen Blanco-Aparicio
@nl
Carmen Blanco-Aparicio
@sl
Carmen Blanco-Aparicio
@sq
P1053
I-3162-2015
P106
P21
P27
P31
P3829
P496
0000-0002-3249-6595
P569
2000-01-01T00:00:00Z